Axsome Therapeutics (AXSM) Operating Margin (2022 - 2026)
Axsome Therapeutics recorded quarterly Operating Margin of 33.14% in Q1 2026, down 164.1% quarter-over-quarter from 51.7% in Q4 2025, and up 1378.0% year-over-year from 2.24% in Q1 2025.
Axsome Therapeutics' Operating Margin history runs 5 years deep, the most recent figure standing at 33.14% for Q1 2026.
- In Q1 2026, Operating Margin rose 1378.0% year-over-year to 33.14%; the TTM figure through Mar 2026 stood at 6.33% (up 7977.0% YoY), while the FY2025 annual figure was 6.03%, up 6672.0% from the prior year.
- Operating Margin came in at 33.14% for Q1 2026 at Axsome Therapeutics, down from 51.7% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 51.7% in Q4 2025 to a low of 14523.4% in Q4 2024.
- A 5-year average of 1010.94% and a median of 89.62% in 2024 frame the typical range for Operating Margin.
- Across the five-year window, Operating Margin slumped 1438601 bps in 2024 and soared 1457510 bps in 2025, its largest moves.
- Axsome Therapeutics' Operating Margin stood at 245.86% in 2022, then surged by 44 bps to 137.39% in 2023, then slumped by 10471 bps to 14523.4% in 2024, then jumped by 100 bps to 51.7% in 2025, then plunged by 164 bps to 33.14% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 33.14%, 51.7%, and 26.97% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn | -33.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.14% |
| Dec 31, 2025 | 51.70% |
| Sep 30, 2025 | -26.97% |
| Jun 30, 2025 | -24.47% |
| Mar 31, 2025 | -46.91% |
| Dec 31, 2024 | -14,523.40% |
| Sep 30, 2024 | -59.78% |
| Jun 30, 2024 | -89.54% |
| Mar 31, 2024 | -89.70% |
| Dec 31, 2023 | -137.39% |
| Sep 30, 2023 | -107.49% |
| Jun 30, 2023 | -139.31% |
| Mar 31, 2023 | -6.74% |
| Dec 31, 2022 | -245.86% |
| Sep 30, 2022 | -251.76% |
| Jun 30, 2022 | -444.23% |